Eyepoint Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative treatments for diseases affecting the eye, particularly those related to retinal and intraocular conditions. The company is dedicated to advancing sustained-release drug delivery systems, enabling patients to receive extended therapeutic benefits from their medications with reduced frequency of administration. Eyepoint's portfolio includes specialized formulations that aim to improve patient outcomes and ease the burden of disease management in ocular health. Through its commitment to research and development, Eyepoint seeks to address unmet medical needs in the field of ophthalmology. Read More
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In EyePoint (EYPT) To Contact Him Directly To Discuss Their Options
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of EyePoint Pharmaceuticals (“EyePoint” or the “Company”) (NASDAQ: EYPT) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or “the Company”) (NASDAQ: EYPT) for violations of the securities laws.
Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Roughly seven out of every ten dollars invested in EyePoint Pharmaceuticals (NASDAQ: EYPT) common stock was wiped out when shares fell nearly 67% following the Company's disclosure that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUGANO wet AMD trial. If you held EYPT shares through that decline, you are encouraged to have your EYPT losses reviewed now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) reported topline results from LUGANO, the first of two Phase III trials evaluating DURAVYU, a vorolanib intravitreal insert, in patients with wet age-related macular degeneration, or wet AMD. The study did not meet its primary non-inferiority endpoint in the fu
Eyepoint Pharmaceuticals (NASDAQ:EYPT) executives said the company remains on track to report top-line data from its Phase 3 wet age-related macular degeneration program for DURAVYU, also known as EYP-1901, beginning in August, with a second pivotal trial expected to follow about two months later.
